Full Press Release Details
Melbourne (Australia) | 4 June 2025
Telix today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix’s first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company’s global manufacturing strategy.
TMS Yokohama will serve as a hub for commercial and clinical supply, and future research and development in the region. It expands Telix’s global production network which includes in-house and partner facilities. Originally opened in 2018, the site comprises a cyclotron and multiple production hot cells and was designed and built by JFE Engineering (JFE) as the Contract Manufacturing Organization (CMO) for TLX250-CDx (Zircaix® [1] , 89 Zr-girentuximab) in Japan and China, including for the ZIRCON-CP study [2] .
Taking over the lease and operational management of this facility will provide greater control over existing clinical supply with the possibility to expand production to other Telix investigational and future commercial products in the region, including Illuccix® (TLX591-CDx, 68 Ga-PSMA-11) and Pixclara® 1 (TLX101-CDx, 18 F-floretyrosine) for Greater Tokyo, and TLX591 ( 177 Lu rosopatamab tetraxetan) for the Asia Pacific region. Further, the Company plans to install Telix’s ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, which it believes will facilitate standardized, high-efficiency and cost-effective production of commercially important medical isotopes.
Darren Patti, Group Chief Operating Officer, Telix said, “We are pleased to announce Telix’s first cyclotron facility in the Asia Pacific region, strategically located in Japan — the world’s second-largest nuclear medicine market. TMS Yokohama enhances our capacity to meet growing demand in the region and supports our mission to provide patients with access to advanced diagnostic and therapeutic radiopharmaceuticals.”
TLX250-CDx, TLX101-CDx and TLX591 have not received a marketing authorization in any jurisdiction.
[1] Brand name subject to final regulatory approval.
[2] ClinicalTrials.gov ID: NCT06750419